etonogestrel


( Last Updated : March 5, 2020)
Generic Name:
etonogestrel
Project Status:
Withdrawn
Therapeutic Area:
Prevention of pregnancy
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0629-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
For the prevention of pregnancy as an open benefit without restrictions
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Prevention of pregnancy
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedAugust 16, 2019
Patient group input closedOctober 07, 2019
Clarification:

- No patient input submission received

Submission receivedSeptember 26, 2019
Submission acceptedOctober 10, 2019
Review initiatedOctober 11, 2019
Draft CADTH review report(s) sent to sponsorJanuary 03, 2020
Comments from sponsor on draft CADTH review report(s) receivedJanuary 14, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsorFebruary 06, 2020
Clarification:

Withdrawn on 19 Feb 2020